Sign in
SELB Stock Price, Chart, Stats & News
Selecta Biosciences, Inc.
Save
135.20M
Market cap
–
Current P/E
–
Forward P/E
SELB chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | -4987.31% |
Net margin | -4658.63% |
Effective tax rate | -6.59% |
ROA | -43.96% |
ROE | 279.62% |
D/E | -0.10x |
Interest coverage ratio | – |
SELB valuation
P/E | – |
P/S | 48.34x |
P/B | -0.18x |
P/CF | -0.31x |
P/FCF | -1.70x |
P/OCF | -0.31x |
PEG | 0.00x |
EV multiple | -7.02x |
About
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to the research and development of innovative nanoparticle immunomodulatory medications aimed at treating and preventing various human ailments. The company's most advanced gene therapy initiative is SEL-302, currently in preclinical development to enhance therapeutic options for methylmalonic acidemia. Among its biologic therapies, SEL-212 is undergoing Phase III clinical trials for the management of chronic refractory gout.
Similar securities
Based on sector and market capitalization
Report issue